Table 3.
Mean biochemical parameters and changes over time during the intensive treatment phase (W0 to W2) in the global study population and during the maintenance phase (W2 to W10) in control and treated patients
| Biochemical parameter | Intensive treatment phase | Maintenance phase | |||||
|---|---|---|---|---|---|---|---|
| W0 (mean ± SD) | W2 (mean ± SD) | % Change W2 vs. W0 | W2 (mean ± SD) | W10 (mean ± SD) | % Change W10 vs. W2 | % Change W10 vs. W0 | |
| Histamine (ng/mg proteins) | |||||||
| Treated | 103.2 ± 188.1 | 36.4 ± 87.9 | −64.8**** | 45.3 ± 115.7 | 112.4 ± 185.8 | 147.8* | 1.35 |
| Control | 27.2 ± 44.3 | 140.0 ± 176.7 | 415.3*** | 46.7 | |||
| p value$ | NS | NS | |||||
| Cathepsin S (ng/mg proteins) | |||||||
| Treated | 1,500.5 ± 976.5 | 450.5 ± 679.9 | −70**** | 317.8 ± 471.6 | 381.1 ± 529.3 | 19.9 | −73.1**** |
| Control | 592.7 ± 834.6 | 1,364.6 ± 941.7 | 130.2** | −14 | |||
| p value$ | 0.0062 | 0.0062 | |||||
| IL-8 (pg/mg proteins) | |||||||
| Treated | 178.3 ± 529.4 | 22.3 ± 79.5 | −87.5* | 41.3 ± 111.9 | 0 | −100 | −100**** |
| Control | 8.0 ± 39.0 | 47.4 ± 94.6 | 495.2 | −59.2** | |||
| p value$ | NS | 0.0207 | |||||
| IL-1RA/IL-1α (pg/μg) | |||||||
| Treated | 293.5 ± 301.2 | 235.9 ± 342.4 | −19.6* | 241.9 ± 392.2 | 102.9 ± 111.0 | −57.5* | −66.8** |
| Control | 230.2 ± 294.7 | 299.6 ± 352.9 | 30.1 | 7.9 | |||
| p value$ | 0.067 | 0.0211 | |||||
| Plakoglobin (arbitrary units) | |||||||
| Treated | 0.936 ± 0.983 | 0.546 ± 0.712 | −41.7** | 0.401 ± 0.388 | 0.328 ± 0.129 | −18.2 | -56.3* |
| Control | 0.624 ± 0.842 | 0.650 ± 0.275 | +4.2** | −39.7 | |||
| p value$ | 0.0095 | NS | |||||
Comparisons versus W0 using Student’s t test, * p < 0.05, ** p < 0.005, *** p < 0.001, **** p < 0.0001
Bold values are statistically significant changes
SD standard deviation, IL interleukin
$Intergroup comparison using an analysis of covariance (ANCOVA)